Female Pattern Hair Loss: a clinical and pathophysiological review

Paulo Müller Ramos, Hélio Amante Miot, Paulo Müller Ramos, Hélio Amante Miot

Abstract

Female Pattern Hair Loss or female androgenetic alopecia is the main cause of hair loss in adult women and has a major impact on patients' quality of life. It evolves from the progressive miniaturization of follicles that lead to a subsequent decrease of the hair density, leading to a non-scarring diffuse alopecia, with characteristic clinical, dermoscopic and histological patterns. In spite of the high frequency of the disease and the relevance of its psychological impact, its pathogenesis is not yet fully understood, being influenced by genetic, hormonal and environmental factors. In addition, response to treatment is variable. In this article, authors discuss the main clinical, epidemiological and pathophysiological aspects of female pattern hair loss.

Conflict of interest statement

Conflicts of Interest: None

Figures

FIGURE 1
FIGURE 1
Female Pattern Hair Loss. Diffuse thinning of the hairs in the frontal and parietal regions, preserving the anterior hair implantation line
FIGURE 2
FIGURE 2
Representative schemes of the hair cycle. A - Normal cycle of the follicle. B - Alterations occurring in baldness: shortening of the anagen phase, increase in the latency period (kenogen phase) and hair follicle minituarization. These alterations may occur together or individually both in FPHL and MPA.
FIGURE 3
FIGURE 3
Representative scheme of the cellular action of androgens. Testosterone (T) enters the cell and is converted by the 5α-reductase enzyme into dihydrotestosterone (DHT). Both T and DHT link themselves to the androgen receptor to promote alterations in cell DNA transcription
FIGURE 4
FIGURE 4
Ludwig´s classification. First proposed classification of MPA. MPA was divided into three intensity degrees.
FIGURE 5
FIGURE 5
Sinclair’s classification. MPA is divided into four levels of intensity based on the normal scalp to the left.
FIGURE 6
FIGURE 6
Olsen´s classification. Other than diffuse thinning, there is also a frontal accentuation opening towards the anterior hair implantation line, creating a “Christmas tree” pattern.
FIGURE 7
FIGURE 7
Hamilton-Nordwood´s classification. Created for the classification of MPA. This pattern rarely affects women
FIGURE 8
FIGURE 8
The basic type (BA) is defined by the shape of the anterior hair implantation line. There are 4 types and they are designated by letters. Type L, there is no hair loss in the frontal hair implantation line, linear pattern Type M, the bilateral frontotemporal recess is more prominent than the central recess. It has the shape of the letter M. Type C, the central recess is more prominent than the frontotemporal recess. It has the shape od the letter C. Types M and C are subdivided into 4 groups, according to the intensity. Type U, the frontal line is behind the vertex. It has the shape of a horseshoe or of the letter U. Type U is subdivided into 3 groups, according to the position of the hair implantation line between the vertex and the occipital protuberance. The specific type (SP) represents the capillary density in certain areas. Type F (frontal), decreased hair density across the top area of the scalp, except the anterior line. Type V is the rarefaction in the vertex region. Specific types are subdivided into 3 groups, according to the intensity. When the patient presents both types (F and V), both types should be described. The fi nal type is decided by the combination of the assigned basic and specific types.
FIGURE 9
FIGURE 9
Dermoscopy of the scalp. A) FPHL. There is great variability in the thickness of the hair shaft, hairs emerging individually from the follicular ostium, reduced follicle density (late fi nding) and incipient pigment network between follicles. B) Normal. Uniformity in the thickness of the hairs and several hairs emerging from the same ostium
FIGURE 10
FIGURE 10
Histopathological examination of FPHL. a) Transverse section evidencing wide variability in diameter of the follicles. b) terminal follicle in detail. c) miniaturized follicle, perifollicular fibrosis and sparse mononuclear inflammatory infiltrate in detail. (HE 40x)

References

    1. Rezende JM. Linguagem médica: Alopécia, alopecia. 2011. [11 nov 2013]. Disponível em: . Internet. a Disponível em: .
    1. Busca no vocabulário. Academia Brasileira de Letras; 2009. [11 nov 2013]. Disponível em: . Internet. Disponível em: .
    1. Descritores em ciências da saúde. Biblioteca Virtual em Saúde; 2013. [11 nov 2013]. Disponível em: . Internet. Disponível em:
    1. Plenck JJ. Doctrina de Morbis Cutaneis. Qua hi morbi in suas classes, genera et species redingtur. Vienna: Van Overbeke; 1776.
    1. Sinclair R. Winding the clock back on female androgenetic alopecia. Br J Dermatol. 2012;166:1157–1158.
    1. Sulzberger MB, Witten VH, Kopf AW. Diffuse alopecia in women. Its unexplained apparent increase in incidence. Arch Dermatol. 1960;81:556–560.
    1. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247–254.
    1. Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat. 1942;71:451–480.
    1. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68:1359–1365.
    1. Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2002;45:S70–S80.
    1. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007;357:1620–1630.
    1. Reid EE1, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66:556–102.
    1. Schmitt JV, Ribeiro CF, Souza FH, Siqueira EB, Bebber FR. Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic. An Bras Dermatol. 2012;87:412–417.
    1. Sociedade Brasileira de Dermatologia SBD Perfil nosológico das consultas dermatológicas no Brasil. An Bras Dermatol. 2006;81:545–554.
    1. Tosti A, Piraccini BM. Androgenetic alopecia. In: Tosti A, Piraccini BM, editors. Diagnosis and treatment of hair disorders: An evidence based atlas. London: Taylor and Francis; 2006. pp. 45–56.
    1. Pereira JM. Propedêutica das doenças dos cabelos e do couro cabeludo. Rio de Janeiro: Atheneu; 2001.
    1. Pereira JM. Alopecia Androgenética (Calvície) na Mulher.2. São Paulo: Di Livros; 2007.
    1. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia) Dermatol Surg. 2001;27:53–54.
    1. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144:297–304.
    1. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10:184–189.
    1. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001;145:95–99.
    1. Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol. 2010;162:843–847.
    1. Su LH, Chen LS, Chen HH. Factors associated with female pattern hair loss and its prevalence in Taiwanese women: a community-based survey. J Am Acad Dermatol. 2013;69:556–577.
    1. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8:201–219.
    1. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439–442.
    1. Tosti A, Pazzaglia M, Soli M, Rossi A, Rebora A, Atzori L, et al. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol. 2004;140:857–858.
    1. Kim BJ, Kim JY, Eun HC, Kwon OS, Kim MN, Ro BI. Androgenetic alopecia in adolescents: a report of 43 cases. J Dermatol. 2006;33:696–699.
    1. Madnani N, Khan K, Chauhan P, Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013;79:310–321.
    1. Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, et al. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: A prospective controlled study. J Am Acad Dermatol. 2013;69:922–930.
    1. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex hormonebinding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361:1152–1163.
    1. Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A, Girón-Prieto MS, Naranjo-Sintes R. Sex hormone-binding globulin and risk of hyperglycemia in patients with androgenetic alopecia. J Am Acad Dermatol. 2011;65:48–53.
    1. Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-specific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol. 2012;167:306–313.
    1. Abdel Fattah NS, Darwish YW. Androgenetic alopecia and insulin resistance: are they truly associated? Int J Dermatol. 2011;50:417–422.
    1. Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol. 2013;149:601–606.
    1. Mansouri P, Mortazavi M, Eslami M, Mazinani M. Androgenetic alopecia and coronary artery disease in women. Dermatol Online J. 2005;11:2–2.
    1. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010;63:420–429.
    1. Messenger AG. Hair through the female life cycle. Br J Dermatol. 2011;165:2–6.
    1. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341:491–497.
    1. Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001;7:293–301.
    1. Rebora A, Guarrera M. Kenogen. A new phase of the hair cycle? Dermatology. 2002;205:108–110.
    1. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4:126ra34–126ra34.
    1. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37:981–990.
    1. Milner Y, Sudnik J, Filippi M, Kizoulis M, Kashgarian M, Stenn K. Exogen, shedding phase of the hair growth cycle: characterization of a mouse model. J Invest Dermatol. 2002;119:639–644.
    1. Kishimoto J, Ehama R, Ge Y, Kobayashi T, Nishiyama T, Detmar M, Burgeson RE. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol. 2000;157:103–110.
    1. Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 2000;14:1181–1185.
    1. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81:449–494.
    1. Randall VA, Jenner TJ, Hibberts NA, De Oliveira IO, Vafaee T. Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles. J Endocrinol. 2008;197:11–23.
    1. Hébert JM, Rosenquist T, Götz J, Martin GR. FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell. 1994;78:1017–1025.
    1. Sawaya ME, Blume-Peytavi U, Mullins DL, Nusbaum BP, Whiting D, Nicholson DW, et al. Effects of finasteride on apoptosis and regulation of the human hair cycle. J Cutan Med Surg. 2002;6:1–9.
    1. Botchkareva NV, Kahn M, Ahluwalia G, Shander D. Survivin in the human hair follicle. J Invest Dermatol. 2007;127:479–482.
    1. Botchkareva NV, Ahluwalia G, Shander D. Apoptosis in the hair follicle. J Invest Dermatol. 2007;127:479–482.
    1. van Scott EJ, Ekel TM. Geometric Relationships Between the Matrix of the Hair Bulb and its Dermal Papilla in Normal and Alopecic Scalp1. J Invest Dermatol. 1958;31:281–287.
    1. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001;45:S81–S86.
    1. Whiting DA. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies. Eur J Dermatol. 2001;11:332–334.
    1. Jahoda CA. Cellular and developmental aspects of androgenetic alopecia. Exp Dermatol. 1998;7:235–248.
    1. Seiberg M, Wisniewski S, Cauwenbergh G, Shapiro SS. Trypsin-induced follicular papilla apoptosis results in delayed hair growth and pigmentation. Dev Dyn. 1997;208:553–564.
    1. Randall VA. Androgens and hair growth. Dermatol Ther. 2008;21:314–328.
    1. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5a-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–1215.
    1. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198:89–95.
    1. Kitagawa T, Matsuda K, Inui S, Takenaka H, Katoh N, Itami S, et al. Keratinocyte growth inhibition through the modification of Wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab. 2009;94:1288–1294.
    1. Zimber MP1, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol. 2011;10:1308–1312.
    1. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578–589.
    1. Finasteride Male Pattern Hair Loss Study Group Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12:38–49.
    1. Yeon JH, Jung JY, Choi JW, Kim BJ, Youn SW, Park KC, 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss J Eur Acad Dermatol. Venereol. 2011;25:211–214.
    1. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298–302.
    1. Gupta AK, Charrette A. The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25:156–161.
    1. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63:252–258.
    1. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4:637–640.
    1. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109:296–300.
    1. Mahé YF, Michelet JF, Billoni N, Jarrousse F, Buan B, Commo S, et al. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000;39:576–584.
    1. Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology. 2010;56:24–38.
    1. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28:755–763.
    1. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol. 2003;121:1561–1564.
    1. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995;98:95S–98S.
    1. Yazdan P. Update on the genetics of androgenetic alopecia, female pattern hair loss, and alopecia areata: implications for molecular diagnostic testing. Semin Cutan Med Surg. 2012;31:258–266.
    1. Lee R, Chang SY, Trinh H, Tu Y, White AC, Davies BS, et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet. 2010;19:1603–1617.
    1. Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol. 1998;110:849–853.
    1. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001;11:309–314.
    1. Ellis JA, Harrap SB. The genetics of androgenetic alopecia. Clin Dermatol Clin Dermatol. 2001;19:149–154.
    1. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116:452–455.
    1. el-Samahy MH, Shaheen MA, Saddik DE, Abdel-Fattah NS, el-Sawi MA, Mahran MZ. Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. Int J Dermatol. 2009;48:584–587.
    1. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg. 1998;3:9–15.
    1. Calvo RM, Asunción M, Sancho J, San Millán JL, Escobar-Morreale HF. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism. J Clin Endocrinol Metab. 2000;85:1735–1740.
    1. Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161:289–294.
    1. Li R, Brockschmidt FF, Kiefer AK, Stefansson H, Nyholt DR, Song K, et al. Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases. PLoS Genet. 2012;8:
    1. Redler S, Dobson K, Drichel D, Heilmann S, Wolf S, Brockschmidt FF, et al. Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss. J Dermatol Sci. 2013;72:186–188.
    1. Heilmann S, Kiefer AK, Fricker N, Drichel D, Hillmer AM, Herold C, et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013;133:1489–1496.
    1. Nuwaihyd R, Redler S, Heilmann S, Drichel D, Wolf S, Birch P, et al. Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss. Arch Dermatol Res. 2014;306:413–418.
    1. Gatherwright J, Liu MT, Gliniak C, Totonchi A, Guyuron B. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. Plast Reconstr Surg. 2012;130:1219–1226.
    1. Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164:5–15.
    1. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466–473.
    1. Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol. 1999;40:106–109.
    1. Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol. 2003;48:253–262.
    1. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53:708–728.
    1. Lee WS, Oh Y, Ji JH, Park JK, Kim do W, Sim WY, et al. Analysis of familial factors using the basic and specific (BASP) classification in Korean patients with androgenetic alopecia. J Am Acad Dermatol. 2011;65:40–47.
    1. Lee WS, Lee HJ, Choi GS, Cheong WK, Chow SK, Gabriel MT, et al. Guidelines for management of androgenetic alopecia based on BASP classification--the Asian Consensus Committee guideline. J Eur Acad Dermatol Venereol. 2013;27:1026–1034.
    1. Lee WS, Ro BI, Hong SP, Bak H, Sim WY, Kim do W, et al. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol. 2007;57:37–46.
    1. Trueb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges. 2010;8:284–297.
    1. Bi MY, Cohen PR, Robinson FW, Gray JM. Alopecia syphilitica-report of a patient with secondary syphilis presenting as moth-eaten alopecia and a review of its common mimickers. Dermatol Online J. 2009;15:6–6.
    1. Rebora A. Acute diffuse and total alopecia of the female scalp: a new subtype of diffuse alopecia areata that has a favorable prognosis-a reply. Dermatology. 2003;207:339–339. author reply 340.
    1. Levine N. Diffuse thinning of scalp hair. Geriatrics. 2000;55
    1. Tosti A, Peluso AM, Misciali C, Venturo N, Patrizi A, Fanti PA. Loose anagen hair. Arch Dermatol. 1997;133:1089–1093.
    1. Lee JY, Hsu ML. Alopecia syphilitica, a simulator of alopecia areata: histopathology and differential diagnosis. J Cutan Pathol. 1991;18:87–92.
    1. Jillson OF. Alopecia. III. Diffuse hair loss (nonscarring) Cutis. 1983;31 465, 469, 472 passim.
    1. Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middleaged women. J Am Acad Dermatol. 1996;35:899–906.
    1. Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol. 2002;47:809–818.
    1. Miteva M, Misciali C, Fanti PA, Tosti A. Histopathologic features of alopecia areata incógnito: a review of 46 cases. J Cutan Pathol. 2012;39:596–602.
    1. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011;24:348–354.
    1. Priego-Recio CM, Rodríguez-Pichardo A, Camacho-Martínez FM. Unusual forms of alopecia areata in a Trichology Unit. J Eur Acad Dermatol Venereol. 2014;28:1394–1396.
    1. Tosti A, Piraccini BM, Sisti A, Duque-Estrada B. Hair loss in women. Minerva Ginecol. 2009;61:445–452.
    1. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006;55:799–806.
    1. Ekmekci TR, Koslu A. Phototrichogram findings in women with androgenetic alopecia. Skin Res Technol. 2006;12:309–312.
    1. Ramos LD, Santili MC, Bezerra FC, Ruiz Mde F, Petri V, Patriarca MT. Dermoscopic findings in female androgenetic alopecia. An Bras Dermatol. 2012;87:691–694.
    1. Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Rudnicka L. Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology. 2009;1:123–130.
    1. Deloche C, de Lacharrière O, Misciali C, Piraccini BM, Vincenzi C, Bastien P, et al. Histological features of peripilar signs associated with androgenetic alopecia. Arch Dermatol Res. 2004;295:422–428.
    1. Gassmueller J, Rowold E, Frase T, Hughes-Formella B. Validation of TrichoScan technology as a fully-automated tool for evaluation of hair growth parameters. Eur J Dermatol. 2009;19:224–231.
    1. Hoffmann R. TrichoScan: combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol. 2001;11:362–368.
    1. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003;121:985–988.
    1. Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgendependent alopecia in women. Clin Endocrinol (Oxf) 1992;36:421–427.
    1. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54:824–844.
    1. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19:831–836.
    1. Freinkel RK, Freinkel N. Hair growth and alopecia in hypothyroidism. Arch Dermatol. 1972;106:349–352.
    1. Rasheed H, Mahgoub D, Hegazy R, El-Komy M, Abdel Hay R, Hamid MA, et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol. 2013;26:101–107.
    1. Amor KT, Rashid RM, Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatol Online J. 2010;16:3–3.
    1. Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011;347:90–96.
    1. Lever WF, Elder DE, Elenitsas R, Johnson BL, Murphy GF. Lever's histopathology of the skin. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
    1. Penha MÁ, Santos PM, Miot HA. Dimensioning the fear of dermatologic diseases. An Bras Dermatol. 2012;87:796–799.
    1. Dolte KS, Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol. 2000;25:637–642.
    1. Tsuboi R, Itami S, Inui S, Ueki R, Katsuoka K, Kurata S, et al. Guidelines for the management of androgenetic alopecia (2010) J Dermatol. 2012;39:113–120.
    1. Gupta AK, Daigle D. The use of low-level light therapy in the treatment of androgenetic alopecia and female pattern hair loss. J Dermatolog Treat. 2014;25:162–163.
    1. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5:541–556.
    1. Vogel JE, Jimenez F, Cole J, Keene SA, Harris JA, Barrera A, et al. Hair restoration surgery: the state of the art. Aesthet Surg J. 2013;33:128–151.
    1. Unger RH. Female hair restoration. Facial Plast Surg Clin North Am. 2013;21:407–417.
    1. Bagatin E, Miot HA. How to design and write a clinical research protocol in Cosmetic Dermatology. An Bras Dermatol. 2013;88:69–75.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner